临床肿瘤学新进展学术研讨会BestofASCOEventin.docx

1、临床肿瘤学新进展学术研讨会BestofASCOEventin2014年临床肿瘤学新进展学术研讨会Best of ASCO Event in China 2014会议日程Program会议第一天 2014年7月11日 (Day 1, July 11, 2014)8:008:15 开幕式 (Opening Ceremony)CSCO代表：吴一龙教授 致辞 (Opening speech by Prof. Yi-Long Wu on behalf of CSCO)ASCO代表：Peter Yu教授 致辞 (Opening speech by Prof. Peter Yu on behalf of A

2、SCO)血液肿瘤专场 (Hematologic Malignancy) 主席(Chair)：马 军(Jun Ma)、王健民(Jian-Min Wang)时间(Time)题目(Topic)讲者(Speaker)8:158:40Abstract 7005Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leu

3、kemia (r/r ALL). BiTE antibody blinatumomab在复发/难治性急性前体B淋巴细胞白血病患者（r/ r ALL）的验证性多中心、开放标签的单臂2期研究。糜坚青(Jian-Qing Mi)Abstract 7008Randomized comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase III RESONAT

4、E trial. ibrutinib与ofatumumab在复发或难治性（R/R）慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的随机比较：来自RESONATE 期试验的结果。Abstract 7026Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial.Ruxolitinib（RUX）在羟

5、基脲耐药或不能耐受的真性红细胞增多症（PV）患者的前瞻性、随机、开放标签的期研究结果：RESPONSE试验。8:408:50专家评述Discussion Topic: A comprehensive overview on molecular targeted therapy for leukemia讨论主题：白血病分子靶向治疗综述李建勇(Jian-Yong Li)8:508:55讨论(Q & A)马 军(Jun Ma)王健民(Jian-Min Wang)李建勇(Jian-Yong Li)泌尿系统肿瘤专场1 (Genitourinary Cancer Session 1) 主席(Chair)：

6、叶定伟(Ding-Wei Ye)、马建辉(Jian-Hui Ma)时间(Time)题目(Topic)讲者(Speaker)8:559:20Abstract LBA2Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. 一项ECOG领导的 III期随机临床试验：激素敏感的新发转移性

7、前列腺癌患者（mPrCa）接受化疗联合内分泌治疗对比单用内分泌治疗对于总生存期(OS)的影响。戴 波(Bo Dai)Abstract 5003Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. PSA复发的前列腺癌患者接受立即雄激素剥夺治疗与延迟雄激素剥夺治疗的比较。Abstract 5008 Phase 3, randomized, placebo-controlled trial of orteronel

8、 (TAK-700) plus prednisone in patients (pts) with chemotherapy-nave metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). 三期、随机、安慰剂对照临床试验（ELM-PC 4试验）：orteronel(tak - 700)联合强的松治疗未接受过化疗的转移性去势抵抗型前列腺癌患者（mCRPC）的研究。9:209:30专家评述Discussion Topic: Feasibility of combined therapy for patie

9、nts with hormone-sensitive prostate cancer讨论主题：对激素敏感型前列腺癌患者进行联合治疗的可行性何志嵩(Zhi-Song He)9:309:35讨论(Q & A)叶定伟(Ding-Wei Ye)马建辉(Jian-Hui Ma)何志嵩(Zhi-Song He)泌尿系统肿瘤专场2 (Genitourinary Cancer Session 2)主席(Chair)：周芳坚(Fang-Jian Zhou)、谢晓冬(Xiao-Dong Xie)时间(Time)题目(Topic)讲者(Speaker)9:3510:00Abstract 5009Nivolumab

10、for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. Nivolumab治疗转移性肾细胞癌（mRCC):一项随机的关于剂量调整的II期临床研究结果。姚 欣(Xin Yao)Abstract 5011Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).MPDL3280A抑制PD-L1及其对转

11、移性膀胱尿路上皮癌患者的临床作用。Abstract 5012Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial.Nivolumab对经治和未治转移性肾细胞癌的免疫调节活性：基于生物标志物的随机临床试验结果。10:0010:10专家评述Discussion Topic: Immunotherapy for R

12、CC?讨论主题：肾癌细胞免疫治疗？王秀问(Xiu-Wen Wang)10:1010:15讨论(Q & A)周芳坚(Fang-Jian Zhou)谢晓冬(Xiao-Dong Xie)王秀问(Xiu-Wen Wang)10:15-10:30 休息 Break恶性黑色素瘤专场 (Melanoma Session)主席(Chair)：郭 军(Jun Guo)、梁 军(Jun Liang)时间(Time)题目(Topic)讲者(Speaker)10:3010:55Abstract 9000Efficacy and safety of the anti-PD-1 monoclonal antibody M

13、K-3475 in 411 patients (pts) with melanoma (MEL).抗PD-1单抗（MK-3475）治疗411例黑色素瘤患者的疗效和安全性研究结果。斯 璐(Lu Si)Abstract LBA9008Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. Ipillimumab与安慰剂辅助治疗III期黑色素瘤术后患者的III期对

14、照研究（EORTC18071）：初步疗效和安全性结果。Abstract 9003Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma.抗PD-1单抗nivolumab（BMS-936558）联合Ipilimumab（IPI）治疗不同BRAF基因突变状态的晚期黑色素瘤患者的生存、疗效持

15、续时间和活化情况的影响。10:55-11:05专家评述Discussion Topic: Adjuvant immunotherapy for resectable melanoma?讨论主题：可手术黑色素瘤的辅助免疫治疗？张晓实(Xiao-Shi Zhang)11:05-11:10讨论(Q & A)郭 军(Jun Guo)梁 军(Jun Liang)张晓实(Xiao-Shi Zhang)胃肠肿瘤专场1 (Gastrointestinal Cancer Session 1)主席(Chair)：沈 琳(Lin Shen)、徐建明(Jian-Ming Xu)时间(Time)题目(Topic)讲者(

16、Speaker)11:10-11:35Abstract 4003Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo- controlled trial. 阿帕替尼治疗晚期胃癌的随机、双盲、安慰剂对照的III期临床研究。张小田(Xiao-Tian Zhang)Abstract 4005RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus pacli

17、taxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum- and fluoropyrimidine- containing combination therapyEfficacy analysis in Japanese and Western patient.RAINBOW：一项ram

18、ucirumab（RAM）对比安慰剂联合紫杉醇治疗一线铂类氟尿嘧啶失败的转移性胃食管结合部或胃腺癌的全球随机、双盲、III期研究日本与西方人群的疗效分析。Abstract 4008Phase III trial to compare capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine- radiotherapy in gastric cancer (GC): The final report on the ARTIST trial. 卡培他滨顺铂（XP）对比XP联合卡陪他滨同步放疗治疗胃癌的III期研究：ARTI

19、ST的最终结果汇报。11:3511:45专家评述Discussion Topic: Anti-angiogenesis for gastric cancer讨论主题：胃癌的抗血管生成治疗郭伟剑(Wei-Jian Guo)11:4511:50讨论(Q & A)沈 琳(Lin Shen)徐建明(Jian-Ming Xu)郭伟剑(Wei-Jian Guo)11:5014:00 午餐和/或卫星会(Lunch and/or satellite symposium)胃肠肿瘤专场2 (Gastrointestinal Cancer Session 2)主席(Chair)：李 进(Jin Li)、徐瑞华(Ru

20、i-Hua Xu)时间(Time)专场(Session)讲者(Speaker)14:0014:25Abstract LBA3CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma o

21、f the colon or rectum (MCRC). CALGB/SWOG 80405：FOLFIRI/mFOLFOX6联合贝伐珠单抗或西妥昔单抗用于KRAS野生型转移性结直肠腺癌初治患者的III期研究。陈 功(Gong Chen)Abstract 3503Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev a

22、s first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207).转移性结直肠癌接受氟化嘧啶（FP）/奥沙利铂/贝伐珠单抗（Bev）联合的标准一线治疗后，FP加Bev或Bev单药维持治疗或不治疗：一项III期非劣效性研究（AIO KRK 0207）。Abstract 3504Final results and subgroup analyses of the phase 3 CAIRO3 study: Mai

23、ntenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC). III期研究CAIRO3的最终结果和亚组分析：转移性结直肠癌接受化疗+贝伐珠单抗诱导化疗后，卡培他滨+贝伐珠单抗维持治疗对比单纯观察。14:2514:35专家评述Discussion Topic: Ultimate words on the role of mai

24、ntenance therapy for metastatic CRC讨论主题：维持治疗在转移性结直肠癌中的价值尘埃落定刘云鹏(Yun-Peng Liu)14:3514:40讨论(Q & A)李 进(Jin Li)徐瑞华(Rui-Hua Xu)刘云鹏(Yun-Peng Liu)胃肠肿瘤专场3 (Gastrointestinal Cancer Session 3) 主席(Chair)：秦叔逵(Shu-Kui Qin)、王理伟(Li-Wei Wang)时间(Time)专场(Session)讲者(Speaker)14:40-15:00Abstract 4000A randomized double-

25、blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).Ruxolitinib联合卡培他滨二线治疗转移性胰腺癌的随机、双盲、安慰剂对照、II期临床研究。袁 瑛(Ying Yuan)Abstract 4006STORM: A phase III randomized, double-blind, placebo-controll

26、ed trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC).STORM研究：索拉非尼用于肝细胞性肝癌切除或射频术后辅助治疗的随机、双盲、安慰剂对照、III期临床试验。15:00-15:15专家评述Discussion Topic: Molecular targeted therapy for pancreatic cancer: reality or just myth?讨论主题：胰腺癌分子靶向治疗：现实还是神话？Margar

27、et A. Tempero翻译：王 峰(Feng Wang)15:15-15:20讨论(Q & A)秦叔逵(Shu-Kui Qin)王理伟(Li-Wei Wang)Margaret A. Tempero乳腺癌专场 1 (Breast Cancer Session 1) 主席(Chair)：江泽飞(Ze-Fei Jiang)、宋尔卫(Er-Wei Song)时间(Time)专场(Session)讲者(Speaker)15:2015:45Abstract 1017 Randomized phase II study of weekly paclitaxel with or without carb

28、oplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer. 每周紫杉醇联合或不联合卡铂序贯环磷酰胺/表阿霉素/5-氟尿嘧啶（CEF）新辅助治疗II/IIIA期HER2-阴性乳腺癌的II期随机试验。王碧芸(Bi-Yun Wang)Abstract 1005 Pathological complete response (pCR) rates after carboplatin-con

29、taining neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. 含卡铂的新辅助化疗治疗BRCA突变乳腺癌或三阴性乳腺癌的病理完全缓解率（pCR）：GeparSixto试验结果。Abstract 1019 Cisplatin with or without rucaparib after preoperative chemotherapy in patients wi

30、th triple- negative breast cancer (TNBC): Hoosier Oncology Group BRE09-146. 顺铂联合或不联合 rucaparib 辅助治疗接受过新辅助化疗的三阴性乳腺癌：Hoosier Oncology Group BRE09-146试验结果。15:4515:55专家评述Discussion Topic: PARP inhibition for breast cancer讨论主题：PARP抑制与乳腺癌殷咏梅(Yong-Mei Yin)15:5516:00讨论(Q & A)江泽飞(Ze-Fei Jiang)宋尔卫(Er-Wei Song

31、)殷咏梅(Yong-Mei Yin)16:00-16:15 休息 Break乳腺癌专场 2 (Breast Cancer Session 2) 主席(Chair)：徐兵河(Bing-He Xu)、刘冬耕(Dong-Geng Liu)时间(Time)专场(Session)讲者(Speaker)16:1516:35Abstract 510 Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. 新辅助治疗研究GEPARSIXTO中三阴性和HER2阳性乳腺癌的免疫基因的表达：卡铂为基础的化疗方案的疗效预测。袁 芃(Peng Yuan)Abstract 511Tracking tumor-spe